B. Riley Has Positive Forecast for Vaxart Q3 Earnings

Vaxart, Inc. (NASDAQ:VXRT) – Research analysts at B. Riley boosted their Q3 2025 earnings per share estimates for shares of Vaxart in a report issued on Thursday, May 29th. B. Riley analyst M. Mamtani now forecasts that the biotechnology company will post earnings per share of ($0.04) for the quarter, up from their previous forecast of ($0.07). B. Riley currently has a “Buy” rating and a $2.00 target price on the stock. The consensus estimate for Vaxart’s current full-year earnings is ($0.39) per share. B. Riley also issued estimates for Vaxart’s Q4 2025 earnings at ($0.06) EPS, FY2025 earnings at ($0.24) EPS, FY2026 earnings at ($0.14) EPS, FY2027 earnings at ($0.16) EPS and FY2028 earnings at ($0.02) EPS.

Vaxart (NASDAQ:VXRT) last posted its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.07). The business had revenue of $20.88 million during the quarter, compared to the consensus estimate of $2.85 million. Vaxart had a negative net margin of 431.61% and a negative return on equity of 110.46%.

Separately, Wall Street Zen upgraded Vaxart to a “hold” rating in a research note on Thursday, May 22nd.

Vaxart Stock Down 6.5%

Vaxart stock opened at $0.44 on Monday. The firm has a 50 day moving average price of $0.40 and a 200-day moving average price of $0.56. Vaxart has a twelve month low of $0.29 and a twelve month high of $1.07. The company has a market capitalization of $99.69 million, a P/E ratio of -1.07 and a beta of 1.27.

Insider Transactions at Vaxart

In other Vaxart news, insider Steven Lo purchased 100,000 shares of the company’s stock in a transaction that occurred on Monday, May 19th. The shares were bought at an average cost of $0.49 per share, for a total transaction of $49,000.00. Following the purchase, the insider now owns 100,000 shares of the company’s stock, valued at $49,000. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 2.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of VXRT. Raymond James Financial Inc. purchased a new position in shares of Vaxart in the fourth quarter valued at $129,000. Sequoia Financial Advisors LLC lifted its holdings in Vaxart by 140.9% during the 4th quarter. Sequoia Financial Advisors LLC now owns 60,213 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 35,213 shares in the last quarter. Geode Capital Management LLC boosted its stake in Vaxart by 2.3% in the 4th quarter. Geode Capital Management LLC now owns 2,601,139 shares of the biotechnology company’s stock worth $1,723,000 after purchasing an additional 57,911 shares during the period. Invesco Ltd. grew its holdings in Vaxart by 48.6% during the 4th quarter. Invesco Ltd. now owns 75,798 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 24,803 shares in the last quarter. Finally, Silverarc Capital Management LLC grew its holdings in Vaxart by 7.8% during the 4th quarter. Silverarc Capital Management LLC now owns 1,077,782 shares of the biotechnology company’s stock valued at $714,000 after buying an additional 77,782 shares in the last quarter. 18.05% of the stock is currently owned by hedge funds and other institutional investors.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.